Detailed Information on Publication Record
2021
The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab
KOLČAVA, Jan, Monika HULOVÁ, Lucie ŘÍHOVÁ, Josef BEDNAŘÍK, Pavel ŠTOURAČ et. al.Basic information
Original name
The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab
Authors
KOLČAVA, Jan (203 Czech Republic, guarantor, belonging to the institution), Monika HULOVÁ (203 Czech Republic, belonging to the institution), Lucie ŘÍHOVÁ (203 Czech Republic), Josef BEDNAŘÍK (203 Czech Republic, belonging to the institution) and Pavel ŠTOURAČ (203 Czech Republic, belonging to the institution)
Edition
NEUROLOGICAL SCIENCES, New York, Springer, 2021, 1590-1874
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30103 Neurosciences
Country of publisher
Italy
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 3.830
RIV identification code
RIV/00216224:14110/21:00120838
Organization unit
Faculty of Medicine
UT WoS
000590250900003
Keywords in English
Natalizumab; Multiple sclerosis; T lymphocytes; Flow cytometry; JC virus
Tags
International impact, Reviewed
Změněno: 18/2/2022 13:40, Mgr. Tereza Miškechová
Abstract
V originále
Background Natalizumab is an effective therapy in the treatment of relapsing-remitting multiple sclerosis; it induces lymphocytosis (NIL, natalizumab-induced lymphocytosis) and changes the peripheral lymphocyte pattern. Methods This study aims to evaluate NIL, peripheral blood lymphocyte subsets, CD4/CD8 ratio, and their impacts on JCV index and clinical data-No Evidence of Disease Activity (NEDA-3) and annualized relapse rate (ARR) in patients treated with natalizumab. Results Forty-one patients (33 women) were included in the study. The mean duration of follow-up on natalizumab treatment was 6.7 +/- 3.2 years. Significant increases in relative lymphocytosis after 1 month, with a median of 40.4% (- 34.1 to + 145.5%) (p < 0.001), and after 1 year (49.0% (- 9.3 to + 127.6%)) (p < 0.001) were found. Significant differences were found after 1 month when comparing NIL between patients JCV-seroconverting (20.6% (- 17.7 to 72.7%)) and stable JCV-seronegative ones (43.5% (- 6.3 to +96.3%)) (p = 0.04). No significant difference NIL level was found between the patients exhibiting NEDA-3 status and those without it. ARR on natalizumab treatment correlated with CD4/CD8 ratio (r = 0.356; p = 0.021); patients who maintained NEDA-3 status over the whole treatment period exhibited a lower CD4/CD8 ratio (1.89 +/- 1.08 vs. 2.5 +/- 0.73; p < 0.04). Conclusion This contribution reports the CD4/CD8 ratio as a possible biomarker for better clinical efficacy of natalizumab in patients exhibiting a lower CD4/CD8 ratio. NIL did not correlate with long-term therapeutic efficacy in patients treated with natalizumab, but was demonstrated as lower in patients JCV-seroconverting in the course of follow-up.
Links
| MUNI/A/1325/2019, interní kód MU |
| ||
| MUNI/A/1600/2020, interní kód MU |
|